{\rtf1\ansi\ansicpg1252\cocoartf949\cocoasubrtf430
{\fonttbl\f0\froman\fcharset0 TimesNewRomanPSMT;\f1\fswiss\fcharset0 ArialMT;}
{\margl1800\margr1600\margt500\margbl1440}
{\pard\sa900\fs50\f0\i Media Release\par}
{\pard\f0\li0\ri0\sa360\sl360\fs22 Basel, 29 January 2007\line \line {\b Tarceva 
: European approval for pancreatic cancer treatment} \line Important new therapy option 
for patients suffering from one of the deadliest cancers\line \line Roche\u8217?s innovative 
cancer drug Tarceva (erlotinib), has been approved today by the European Commission for the treatment 
of patients with metastatic pancreatic cancer, in combination with a standard chemotherapy, gemcitabine. 
Tarceva is the first treatment in over a decade to have shown a significant survival benefit in treating 
patients with this devastating disease. Pancreatic cancer has the highest one-year mortality rate of 
any cancer and is Europe\u8217?s sixth deadliest cancer.{\super 1}  \line \line \u8220?This 
is a much needed treatment advance for patients suffering with this difficult-to-treat disease,\u8221? said 
William M. Burns, CEO Roche Pharmaceuticals. \u8220?The approval of Tarceva in combination with gemcitabine 
chemotherapy offers patients and their families some real hope.\u8221?\line \line The 
approval was based on data from the pivotal PA.3 Phase III Study,{\super 2}  which 
show that for patients with metastatic disease, treatment with Tarceva plus gemcitabine results in significantly 
longer survival (25 percent) compared to gemcitabine alone. In addition, a higher percentage of these 
patients were alive at 12 months in the group treated with Tarceva plus gemcitabine, compared to those 
treated with chemotherapy alone (21 percent v. 15 percent). The approval follows a positive recommendation 
from the European Committee for Medicinal Products for Human Use (CHMP) in December 2006. \line \line Pancreatic 
cancer is the sixth most frequently occurring cancer in Europe.{\super 1}  In 2002, 
there were more than 78,000 new cases of pancreatic cancer diagnosed in Europe, with a death rate of 
approximately 82,000 people per year. {\super 3}  Pancreatic cancer is difficult to 
treat as it is often resistant to chemotherapy and radiotherapy and tends to spread quickly to other 
parts of the body, leading to a short life expectancy.\line \u8220?Tarceva generates renewed optimism 
for patients and physicians,\u8221? said Professor Eric Van Cutsem, of the University Hospital of Gasthuisberg, 
Belgium. \u8220?This approval marks a clear step forward in providing them with another treatment option for 
battling this terrible disease.\u8221? \line \line {\b About the PA3} {\super 2} {\b  
study} \line The results of the double-blind, placebo-controlled Phase III study conducted 
by the National Cancer Institute of Canada, Clinical Trials Group at Queens University and involving 
569 patients showed:\par}{\pard\f0\li440\ri0\sl360\fs22 - Treatment with Tarceva plus 
gemcitabine in patients with metastatic 
pancreatic cancer resulted in significantly improved overall survival compared to gemcitabine alone 
(25%)\par}{\pard\f0\li440\ri0\sl360\fs22 - 21% of these patients receiving Tarceva plus gemcitabine 
were alive after one 
year, compared to 15% on gemcitabine alone\par}{\pard\f0\li440\ri0\sl360\fs22 - Overall, patients receiving 
Tarceva plus 
gemcitabine experienced significantly longer progression-free survival of 30%\par}{\pard\f0\li440\ri0\sl360\fs22 - Tarceva 
plus gemcitabine was generally well tolerated by patients\line \par}\line {\pard\f0\li0\ri0\sa360\sl360\fs22 Tarceva 
plus 
gemcitabine is already approved for the treatment of locally advanced, unresectable or metastatic pancreatic 
cancer in 15 countries including America and Australia. Tarceva is approved in the US and across the 
European Union for patients with locally advanced or metastatic non small cell lung cancer (NSCLC) after 
failure of at least one prior chemotherapy regimen. \line \line {\b About 
Tarceva} \line Tarceva (erlotinib) is a small molecule that targets the human epidermal 
growth factor receptor (HER1) pathway. HER1, also known as EGFR, is a key component of this signalling 
pathway, which plays a role in the formation and growth of numerous cancers. Tarceva blocks tumour cell 
growth by inhibiting the tyrosine kinase activity of the HER1 signalling pathway inside the cell. \line \line Taken 
as an oral, once-daily therapy, Tarceva is the only EGFR-inhibitor to have demonstrated a survival benefit 
in lung and pancreatic cancer. Currently most lung and pancreatic cancer patients are treated wholly 
with chemotherapy which can be very debilitating due to its toxic nature. Tarceva works differently 
to chemotherapy by specifically targeting tumour cells, and avoids the typical side-effects of chemotherapy.\line \line Tarceva 
is approved in the US and across the European Union for patients with locally advanced or metastatic 
non small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen. It is also 
approved in the US for the first-line treatment of patients with locally advanced, unresectable or metastatic 
pancreatic cancer, in combination with gemcitabine chemotherapy.\line Tarceva is currently 
being evaluated in an extensive clinical development programme by a global alliance among OSI Pharmaceuticals, 
Genentech and Roche, focussing on earlier stages of NSCLC. Additionally, Tarceva is being studied in 
combination with Avastin in NSCLC and in a wide variety of other solid tumour types. \line \line {\b About 
Roche}  \line Headquartered in Basel, Switzerland, Roche is one of the world\u8217?s leading 
research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of 
innovative products and services for the early detection, prevention, diagnosis and treatment of disease, 
the Group contributes on a broad range of fronts to improving people\u8217?s health and quality of life. Roche 
is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and 
a market leader in virology. Roche employs roughly 70,000 people in 150 countries and has R&D agreements 
and strategic alliances with numerous partners, including majority ownership interests in Genentech 
and Chugai. Additional information about the Roche Group is available on the Internet (www.roche.com (http://www.roche.com)).\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 All 
trademarks used or mentioned in this release are protected by law.\par}\line \line \line {\b Further 
information} \line - About Genentech (http://www.gene.com)\line - 
About OSI Pharmaceuticals (http://www.osip.com)\line - About cancer (http://www.health-kiosk.ch/start_krebs)\line - 
Roche in Oncology (http://www.roche.com/pages/downloads/company/pdf/mboncology05e.pdf)\line \line {\pard\f0\li0\ri0\sa360\sl360\fs18 References\line 1) 
Michaud DS. 2004. Epidemiology of pancreatic cancer Minerva Chir. Apr; 59(2):99-111\line 2) 
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients 
with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical 
Trials Group [NCIC-CTG]. (Abstract #1, ASCO 2005) \line 3) \u160?Ferlay J et al. GLOBOCAN 
2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, Version 2.0, Lyon; 
IARC Press 2004\par}\par}{\pard\f0\li0\ri0\sa360\sl360\fs22 \par}
{\pard \par}
{\pard\sb180\f1\fs22 {\b F. Hoffmann-La Roche Ltd}\line 4070 Basel\line Switzerland \par}
{\pard\sb180\f1\fs22 Corporate Communications\line Roche Group Media Relations \par}
{\pard\sb180\f1\fs22 Tel. +41 61 688 88 88\line Fax +41 61 688 27 75\line www.roche.com \par}
}